Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 26;17(8):990.
doi: 10.3390/ph17080990.

Development and Optimization of Nasal Composition of a Neuroprotective Agent for Use in Neonatology after Prenatal Hypoxia

Igor Belenichev  1 , Olena Aliyeva  2 , Bogdan Burlaka  3 , Kristina Burlaka  4 , Oleh Kuchkovskyi  1 , Dmytro Savchenko  5 , Valentyn Oksenych  6 , Oleksandr Kamyshnyi  7
Affiliations

Development and Optimization of Nasal Composition of a Neuroprotective Agent for Use in Neonatology after Prenatal Hypoxia

Igor Belenichev et al. Pharmaceuticals (Basel). .

Abstract

The intranasal route of drug administration is characterized by high bioavailability and is considered promising for rapid delivery of drugs with systemic action to the central nervous system (CNS), bypassing the blood-brain barrier. This is particularly important for the use of neuroprotective drugs in the treatment of brain tissue damage in infants caused by the effects of intrauterine hypoxia. The creation of new dosage forms for neonatology using mathematical technologies and special software in pharmaceutical development allows for the creation of cerebroprotective drugs with controlled pharmaco-technological properties, thus reducing time and resources for necessary research. We developed a new nasal gel formulation with Angiolin using a Box-Behnken experiment design for the therapy of prenatal CNS damage. It was found that the consistency characteristics of the nasal gel were significantly influenced by the gelling agent and mucoadhesive component-sodium salt of carboxymethylcellulose. We optimized the composition of nasal gel formulation with Angiolin using the formed models and relationships between the factors. The optimized nasal gel composition demonstrated satisfactory thixotropic properties. The 1% gel for neuroprotection with Angiolin, developed for intranasal administration, meets all safety requirements for this group of drug forms, showing low toxicity and no local irritant or allergic effects.

Keywords: angiolin; intranasal gel; neuroprotection; prenatal hypoxia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
3D illustration of the relationship between the variable factors (Na CMC, D-panthenol) and viscosity characteristics of nasal gels.
Figure 2
Figure 2
3D illustration of the relationship between the variable factors (Na CMC, D-Panthenol) and the percentage of Angiolin release intensity from nasal gels.
Figure 3
Figure 3
3D illustration of the relationship between the variable factors (Na CMC, Tween-80) and the percentage of Angiolin release intensity from nasal gels.
Figure 4
Figure 4
3D illustration of the relationship between modifying factors (Tween-80, D-Panthenol) and the percentage of Angiolin release intensity from nasal gels.
Figure 5
Figure 5
Thixotropy test of optimized nasal gel formulation with Angiolin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gomez D., Martinez J.A., Hanson L.R., Frey W.H., Toth C.C. Intranasal treatment of neurodegenerative diseases and stroke. Front. Biosci. 2012;4:74–89. doi: 10.2741/s252. - DOI - PubMed
    1. Madden S., Carrazana E., Rabinowicz A.L. Optimizing Absorption for Intranasal Delivery of Drugs Targeting the Central Nervous System Using Alkylsaccharide Permeation Enhancers. Pharmaceutics. 2023;15:2119. doi: 10.3390/pharmaceutics15082119. - DOI - PMC - PubMed
    1. Crowe T.P., Hsu W.H. Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System. Pharmaceutics. 2022;14:629. doi: 10.3390/pharmaceutics14030629. - DOI - PMC - PubMed
    1. Veronesi M.C., Alhamami M., Miedema S.B., Yun Y., Ruiz-Cardozo M., Vannier M.W. Imaging of intranasal drug delivery to the brain. Am. J. Nucl. Med. Mol. Imaging. 2020;10:1–31. - PMC - PubMed
    1. Dwibhashyam V.S., Nagappa A.N. Strategies for enhanced drug delivery to the central nervous system. Indian J. Pharm. Sci. 2008;70:145–153. - PMC - PubMed

LinkOut - more resources